{
    "clinical_study": {
        "@rank": "164857", 
        "arm_group": {
            "arm_group_label": "Debio 1347 (CH5183284)", 
            "arm_group_type": "Experimental", 
            "description": "Eligible patients will receive Debio 1347(CH5183284)"
        }, 
        "brief_summary": {
            "textblock": "This study is primarily designed to assess the safety and the tolerability of Debio\n      1347(CH5183284) at increasing doses in patients with advanced solid malignancies, whose\n      tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 genes."
        }, 
        "brief_title": "Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumours", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Signed written informed consent approved before undertaking any study-specific\n             procedures.\n\n          2. Patients with advanced solid malignancies, whose tumours have an alteration of the\n             FGFR 1, 2 or 3 genes, confirmed by local site genetic tests on a biopsy.\n\n          3. Age \u2265 18 years.\n\n          4. Eastern Cooperative  Oncology Group (ECOG) Performance Status (PS) \u2264 2.\n\n          5. Histologically or cytologically confirmed advanced solid tumour that has recurred or\n             progressed following standard therapy, has not responded to standard therapy or for\n             which no standard therapy exists.\n\n          6. Patients have measurable or non-measurable disease.\n\n          7. Adequate organ function in bone marrow, cardiovascular, hepatic and renal systems.\n\n        Exclusion Criteria:\n\n          1. History of hypersensitivity to any of the excipients in the Debio 1347 (CH5183284)\n             formulation.\n\n          2. History of another malignancy, unless patient has been disease-free for 5 years.\n\n          3. Patients with brain tumours and/or brain metastases unless brain metastases are\n             asymptomatic and they are not currently receiving corticosteroids and/or\n             anticonvulsants.\n\n          4. History and/or current evidence of endocrine alteration of calcium-phosphate\n             homeostasis.\n\n          5. History and or current evidence of ectopic mineralisation/calcification including but\n             not limited to the soft tissue, kidneys, intestine, myocardium and lung with the\n             exception of calcified lymph nodes and asymptomatic coronary calcification.\n\n          6. Concomitant use of a systemic steroid or any other drug that affect calcium and\n             phosphorus metabolism.\n\n          7. Corneal disease, such as bullous or band keratopathy, corneal desquamation,\n             keratitis, corneal ulcer, or keratoconjunctivitis.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "106", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01948297", 
            "org_study_id": "Debio 1347-101"
        }, 
        "intervention": {
            "arm_group_label": "Debio 1347 (CH5183284)", 
            "description": "Debio 1347 (CH5183284) will be administered orally once daily on a continuous basis 28 day cycles until progression of disease or unacceptable toxicity.", 
            "intervention_name": "Debio 1347 (CH5183284)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Mitogens"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 22, 2014", 
        "link": {
            "url": "http://www.debiopharm.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Massachusetts General Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martin Voss, MD", 
                    "phone": "646-422-4631"
                }, 
                "facility": {
                    "address": {
                        "city": "New-York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan-Kettering Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Josep Tabernero, MD", 
                    "phone": "+34-93-489-43-01"
                }, 
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain"
                    }, 
                    "name": "Vall d'Hebron University Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes", 
        "other_outcome": {
            "description": "Assessment of preliminary antitumor activity of Debio 1347; Overall response rate = complete response + partial response", 
            "measure": "Overall response rate", 
            "safety_issue": "No", 
            "time_frame": "Every 8 weeks from the date of baseline visit"
        }, 
        "overall_contact": {
            "last_name": "Claudio Zanna, MD", 
            "phone": "+41213210111"
        }, 
        "overall_contact_backup": {
            "last_name": "Christian Aeschlimann, MS", 
            "phone": "+41213210111"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Hospital", 
            "last_name": "Jos\u00e9 Baselga, MD, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisions.", 
            "measure": "Incidence rate of dose limiting toxicities (DLTs) of Debio 1347", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01948297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions", 
                "measure": "Safety and tolerability of Debio 1347 combination at the recommended dose (RDE) for expansion", 
                "safety_issue": "Yes", 
                "time_frame": "Every 28 days from baseline visit to 28 days after study drug discontinuation"
            }, 
            {
                "measure": "Markers of FGFR inhibition in plasma and tumor", 
                "safety_issue": "No", 
                "time_frame": "Baseline and day 8"
            }, 
            {
                "description": "Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of Debio 1347", 
                "measure": "Time vs. concentration profile of Debio 1347", 
                "safety_issue": "Yes", 
                "time_frame": "Every 28 days for up to the end of the study"
            }
        ], 
        "source": "Debiopharm International SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Debiopharm International SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}